Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Discovery Chemistry Congress

Vicki Nienaber's Biography

Vicki Nienaber, CSO, Zenobia Therapeutics, Inc.

Dr. Vicki Nienaber has been a leader in the fragment-based drug discovery field since its inception at Abbott laboratories during the 1990's. At Abbott, she worked alongside NMR screeners pairing SARbyNMR with x-ray for drug discovery and is primary inventor of the first crystallographic screening method still in use today. Dr. Nienaber has led numerous programs including SGX collaborations with Eli Lilly, Novartis and SGX internal FBLD pipeline. Dr. Nienaber also built the fragment screening platform at Abbott laboratories including invention of the first crystal mounting robot (ACTOR, now marketed by Rigaku). She also fully implimented the structural biology platform at SGX coordinating between engineers, programmers and scientists.

Vicki Nienaber Image

Fragment-Based Lead Discovery in CNS Disease

Tuesday, 13 March 2012 at 14:15

Add to Calendar ▼

Despite central nervous system (CNS) diseases representing one of the largest unmet medical needs, treatments have lagged behind other therapeutic areas because of the distinct challenges these diseases present. The use of FBLD to uniquely address these challenges will be discussed.

Add to Calendar ▼2012-03-13 00:00:002012-03-14 00:00:00Europe/LondonDiscovery Chemistry CongressDiscovery Chemistry Congress in Munich, GermanyMunich,